Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilafucept alfa
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Rilafucept alfa (SHR-1701) is a bifunctional fusion protein designed to simultaneously inhibit the programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β) signaling pathways. Developed by Jiangsu Hengrui Pharmaceuticals, it consists of a humanized anti-PD-L1 monoclonal antibody fused to the extracellular domain of the human TGF-β receptor type II (TGFβRII). By targeting both pathways, rilafucept alfa aims to overcome TGF-β-mediated immunosuppression in the tumor microenvironment, thereby enhancing the anti-tumor activity of PD-L1 blockade. It is currently being evaluated in clinical trials for various solid tumors, including biliary tract cancer, gastric cancer, and non-small cell lung cancer.
- Other names
- rilafucept alfaSHR-1701SHR1701SHR 1701
02
Targets
TGFB2 (Transforming growth factor beta 2)TGFB3 (Transforming growth factor beta 3)TGFB1 (Transforming growth factor Beta-1 proprotein)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on rilafucept alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilafucept alfa.